Last reviewed · How we verify
Tinosorb S (BEMOTRIZINOL)
Tinosorb S, also known as bemotrizinol, is a small molecule sunscreen agent developed by a pharmaceutical company. It is used to protect the skin from the sun's ultraviolet (UV) rays. As a patented product, its commercial status is not yet generic. Key safety considerations include its potential to cause skin irritation and allergic reactions. Tinosorb S is used to prevent sunburn and reduce the risk of skin cancer.
At a glance
| Generic name | BEMOTRIZINOL |
|---|---|
| Drug class | Adenosine Receptor Agonist [EPC] |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Sunscreen agent
Common side effects
Key clinical trials
- Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial (PHASE3)
- Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol (PHASE2)
- Phototoxicity Potential of 6% Bemotrizinol (PHASE2)
- Photoallergic Potential of 6% Bemotrizinol (PHASE2)
- Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study (PHASE1)
- Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma (PHASE4)
- Multi-Centre European Photopatch Test Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tinosorb S CI brief — competitive landscape report
- Tinosorb S updates RSS · CI watch RSS